In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.
Study design: epidemiological point prevalence study Target population: Patients with haloperidol treatment The following aspects will be investigated: * The medication profiles will be checked for drug interactions with risk of QT-prolongation. * Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected. * Safety measurements (e.g. ECG) will be documented.
Study Type
OBSERVATIONAL
Enrollment
222
Universitair Ziekenhuis Leuven
Leuven, Belgium
QTc-interval (corrected for heart rate)
Time frame: maximum one year before inclusion / one week after inclusion
number of drug interactions (with risk of QT-prolongation)
Time frame: one week before/after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.